Aug. 1 at 4:10 PM
$CRVS While Soquelitinib and Obefazimod have distinct upstream MOAs, they converge on modulating key inflammatory cytokines and immune cell subsets, especially in autoimmune and inflammatory contexts. The early success of Obefazimod supports the broader thesis that selective immune modulation is a viable and lucrative therapeutic approach — lending indirect credibility to Soquelitinib's potential if efficacy is demonstrated in larger trials.
